Completed PHASE1 INTERVENTIONAL 2-arm NCT02212782

the Pharmacokinetic Profiles of Linagliptin With DW1029M (PLID)

A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Linagliptin After Oral Administration in Healthy Male Volunteer

Sponsor: Dong Wha Pharmaceutical Co. Ltd.

Conditions Healthy

Interventions DW1029M 1200mg and Linagliptin 5mg Linagliptin 5mg

Updated 6 times since 2017 Last updated: Jun 25, 2015 Started: Sep 30, 2014 Primary completion: Nov 30, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Dong Wha Pharmaceutical Co. Ltd. leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong Wha Pharmaceutical Co. Ltd.

Data source: Dong Wha Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jeonju, South Korea